17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation

Concept and Molecular Pathogenesis of Cutaneous Field Cancerisation

The concept of field cancerisation (originally introduced in oral oncology by Slaughter in 1953 and systematically validated in dermato-oncology) describes the presence of extensive epithelial areas that have sustained severe, chronic photodamage and harbor widespread genetic alterations. Although surrounding tissue may appear clinically unremarkable or show only subtle solar elastosis, it is biologically primed for neoplastic transformation. In cutaneous medicine, field cancerisation underpins the continuous, multifocal emergence of precancerous dysplasias, in situ carcinomas, and invasive keratinocyte carcinomas across chronically sun-exposed anatomic regions such as the scalp, face, neck, and dorsal upper extremities.

Chronically Sun-Exposed Cutaneous Field (UVB Radiation: 290–320 nm)
   │
   ▼
Direct Photochemical DNA Damage
   ├── Cyclobutane Pyrimidine Dimers (CPDs)
   └── Pyrimidine-Pyrimidone (6-4) Photoproducts
   │
   ▼
Nucleotide Excision Repair (NER) Saturation / Failure
   │
   ▼
Characteristic UV-Signature Transition Mutations (C → T and CC → TT)
   │
   ▼
Inactivating TP53 Gene Mutations (Loss of G1/S Checkpoint & Apoptosis)
   │
   ▼
Clonal Proliferation of Atypical Keratinocytes
   │
   ├── Subclinical Molecular Field Defect (Mutations in Normal-Appearing Skin)
   ├── Actinic Keratosis (KIN I → KIN II → KIN III)
   ├── Bowen Disease (Full-Thickness In Situ Squamous Cell Carcinoma)
   └── Invasive Cutaneous Squamous Cell Carcinoma (cSCC)

Molecular Drivers and the Central Role of TP53

1. Ultraviolet-Induced Mutagenesis: Ultraviolet B (UVB, 290–320 nm) acts as a complete direct carcinogen. Absorption of UVB photons by epidermal DNA induces covalent bonds between adjacent pyrimidine bases, creating cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts. Incomplete or error-prone repair by the nucleotide excision repair (NER) machinery leads to characteristic "UV-signature" transitions: single cytosine-to-thymine (C → T) and tandem dipyrimidine (CC → TT) base substitutions.
2. TP53 Inactivation and Clonal Selection: The TP53 tumor suppressor gene (located on chromosome 17p13.1) encodes the p53 transcription factor, the "guardian of the genome." In normal keratinocytes, severe DNA damage triggers p53-mediated G1/S cell-cycle arrest (via p21/CDKN1A) to allow enzymatic repair, or initiates apoptosis (via BAX, PUMA, and caspase-3) if damage is irreparable. Inactivating TP53 mutations abolish these protective checkpoints, allowing DNA-damaged cells to evade apoptosis and continue mitotic cycling.
3. Polyclonal Microscopic Fields: Chronic repeated solar exposure exerts positive selective pressure, causing mutated keratinocytes to expand into large, contiguous intraepidermal clones. Modern genomic mapping demonstrates that a single square centimeter of sun-damaged, clinically normal skin from the forehead or bald scalp contains hundreds of distinct, overlapping polyclonal patches harboring somatic TP53, NOTCH1, NOTCH2, and FAT1 mutations. Consequently, eradicating an isolated visible lesion without treating the surrounding actinic field leaves the patient vulnerable to primary field recurrences and de novo invasive malignancies.

---

Actinic Keratosis: Definition and Clinical Spectrum

Actinic keratosis (AK), also termed solar keratosis or keratinocyte intraepithelial neoplasia (KIN), is the most frequent intraepidermal keratinocyte dysplasia encountered in European dermatological practice. It is formally classified as an in situ premalignant neoplasm arising on a continuous biological spectrum that can progress to invasive cutaneous squamous cell carcinoma (cSCC).

Clinical Morphology and Anatomic Distribution

• Presentation: Ill-defined, rough, gritty, sandpaper-like scaly macules, papules, or thin plaques. The background skin typically displays profound solar elastosis, irregular mottling, telangiectasias, and senile purpura.
• Coloration: Varies from normal skin color to erythematous, yellowish-brown, grayish, or hyperpigmented.
• Sites of Predilection: Photodistributed areas receiving lifelong cumulative solar exposure: the scalp of balding men, forehead, temporal regions, helix and antihelix of the ears, bridge of the nose, lower lip vermilion border (actinic cheilitis), dorsal hands, and extensor surfaces of the forearms.

Olsen Clinical Grading System

The Olsen clinical classification stratifies actinic keratoses based on palpability and hyperkeratotic thickness, guiding therapeutic selection:

Cutaneous Horn (Cornu Cutaneum)

A cutaneous horn (cornu cutaneum) is an exaggerated, conical, hyperkeratotic projection of cohesive keratin whose height comprises at least half of its greatest base diameter. It resembles an animal horn.

• Crucial Diagnostic Principle: A cutaneous horn is a clinical-morphological description, never a histological diagnosis. The horn itself consists purely of compact, dead, anucleate or parakeratotic stratum corneum.
• Underlying Histopathological Substrate: The clinical importance of a cutaneous horn resides entirely in the underlying epidermal pathology at its base:
  • ~40–50% represent benign conditions (seborrhoeic keratosis, verruca vulgaris, trichilemmoma, histiocytoma).
  • ~30–40% represent premalignant or in situ neoplasms (actinic keratosis, Bowen disease).
  • ~15–20% harbor an underlying, invasive cutaneous squamous cell carcinoma.
• Clinical Trap and Management Mandate: Superficial cryotherapy, topical destructive creams, or blind curettage of a cutaneous horn without obtaining histological architecture of the base is malpractice. Standard clinical practice mandates a complete, deep shave or excisional biopsy encompassing the full thickness of the dermal base to evaluate for invasive squamous cell carcinoma.

---

Histopathologic Classification: The KIN System and the Flag Sign

Histopathologically, actinic keratoses are characterized by atypical keratinocytes exhibiting enlarged, hyperchromatic, pleomorphic nuclei, clumped chromatin, prominent nucleoli, loss of normal polarity, and increased cytoplasmic basophilia, accompanied by dyskeratotic cells.

Röwert-Huber AK I–III Grading and KIN Terminology

The KIN grading classification mirrors cervical intraepithelial neoplasia (CIN), categorizing intraepidermal dysplasia based on the depth of atypical keratinocyte involvement within the stratified squamous epidermis:

Stratum Corneum  [ Parakeratosis / Orthokeratosis ]
                 ─────────────────────────────────
Upper Third      [ Granular / Upper Spinous Cells ]  <── KIN III involves all layers
                 ─────────────────────────────────
Middle Third     [ Mid Spinous Keratinocytes ]       <── KIN II involves lower 2/3
                 ─────────────────────────────────
Lower Third      [ Basal and Parabasal Layers ]      <── KIN I restricted to lower 1/3
                 ═════════════════════════════════  <── Basement Membrane (Strictly INTACT)
Papillary Dermis [ Solar Elastosis / Lymphocytes ]

1. KIN I: Atypical, dysplastic, crowded keratinocytes are strictly restricted to the lower third (basal and parabasal layers) of the epidermis. The upper two-thirds retain normal stratification, orderly maturation, and a preserved stratum granulosum.
2. KIN II: Dysplastic keratinocytes showing marked hyperchromasia, nuclear enlargement, and loss of polarity occupy the lower two-thirds of the epidermis. Occasional mitotic figures are identified in the mid-epidermal spinous layers.
3. KIN III (Bowenoid AK): Full-thickness cytological atypia, cellular pleomorphism, and disordered maturation involve the entire thickness of the epidermis, from the basal layer to the stratum granulosum. Mitotic figures (including atypical forms) and dyskeratotic cells are distributed at all levels. The dermo-epidermal basement membrane remains completely intact, without invasion into the underlying papillary dermis.

The Pathognomonic "Flag Sign"

A hallmark histopathological feature of actinic keratoses on light microscopy is the flag sign:

• Pathophysiology: Folliculo-infundibular and acrosyringial (sweat duct) epithelium possess independent, deeper adnexal stem cell niches that are relatively shielded from direct solar radiation. As adnexal keratinocytes migrate upward to populate the skin surface around ostia, they mature normally.
• Microscopic Appearance: Alternating vertical columns of compact parakeratosis (nucleated stratum corneum produced by atypical, dysplastic interadnexal keratinocytes) and basket-weave orthokeratosis (anucleate stratum corneum produced by the spared, normally maturing adnexal ostial epithelium). This alternating horizontal and vertical striping closely resembles a national flag.

Additional Histopathologic Variants

• Hypertrophic AK: Marked hyperkeratosis with prominent papillomatosis; often misdiagnosed clinically as a cutaneous horn or verruca.
• Atrophic AK: Marked epidermal thinning with flattening of the rete ridges; dysplastic atypical cells are concentrated in the single basal cell layer.
• Pigmented AK: Abundant melanin synthesis within atypical basal keratinocytes accompanied by melanophages in the papillary dermis; clinically and dermoscopically mimics lentigo maligna.
• Acantholytic AK: Loss of intercellular bridges (desmosomes) producing suprabasal clefts and intraepidermal pseudoglandular spaces; must be differentiated from Darier disease, Grover disease, or acantholytic SCC.
• Lichenoid AK: Marked band-like, lichenoid lymphocytic infiltrate hugging the dermo-epidermal junction with basal vacuolar degeneration, Civatte bodies, and apoptotic keratinocytes; can be confused with lichen planus-like keratosis (LPLK).

---

Bowen Disease (Squamous Cell Carcinoma In Situ)

Bowen disease (squamous cell carcinoma in situ) represents an autonomous intraepidermal malignancy of keratinocytes where full-thickness dysplasia has developed without yet breaching the dermo-epidermal basement membrane.

Clinical Presentation and Differential Diagnosis

• Clinical Manifestation: Slowly expanding, well-demarcated, irregularly rounded, erythematous, scaly or crusted plaque. The surface may appear verrucous, velvety, or fissured. Lesions are typically solitary, persistent, and entirely refractory to topical corticosteroids.
• Anatomic Distribution: Common on the lower limbs of elderly females, head and neck, trunk, and dorsal hands.
• Clinical Mimics: Often misdiagnosed for months or years as nummular eczema, localized plaque psoriasis, superficial basal cell carcinoma, or tinea incognito. Induration, ulceration, or nodular elevation within a longstanding Bowen plaque heralds progression into invasive cutaneous squamous cell carcinoma (occurring in ~3–5% of cutaneous lesions).

Erythroplasia of Queyrat: The Mucosal Variant

Erythroplasia of Queyrat is Bowen disease of the mucosal surfaces, almost exclusively affecting the glans penis, coronal sulcus, or prepuce of uncircumcised elderly men (and rarely the vulva in postmenopausal women).

• Appearance: A solitary, glistening, bright red, velvety, sharply defined, moist plaque with minimal or absent scaling.
• Etiology: Strong association with chronic inflammation, lack of neonatal circumcision, smegma accumulation, and high-risk oncogenic human papillomaviruses (HPV types 16 and 18).
• Malignant Transformation Risk: In stark contrast to cutaneous Bowen disease, erythroplasia of Queyrat carries an exceptionally high progression rate to deeply invasive squamous cell carcinoma (up to 10–30%), with early metastasis to inguinal lymph nodes. Immediate histological verification and complete eradication are paramount.

Histopathology of Bowen Disease

Microscopic examination demonstrates a characteristic "windblown" architecture:

• Full-Thickness Epidermal Disorganisation: Total loss of orderly keratinocyte stratification and architectural maturation from the basal layer to the stratum corneum.
• Severe Cytological Pleomorphism: Markedly enlarged, vesicular, hyperchromatic nuclei, prominent nucleoli, multinucleated keratinocytes (giant "clumping cells"), and intensely eosinophilic, dyskeratotic cells scattered haphazardly.
• High Mitotic Index: Atypical, bizarre mitotic figures (tripolar, multipolar) situated high within the middle and upper epidermal layers, far above the basal compartment.
• Intact Dermal-Epidermal Junction: The basement membrane is preserved and intact; no nests or single cells breach the underlying dermis. Solar elastosis and a dense chronic dermal inflammatory infiltrate are consistently present.

---

European Consensus Management: Lesion-Directed vs Field-Directed Therapies

Modern European dermatological guidelines (European Dermatology Forum [EDF], European Academy of Dermatology and Venereology [EADV], and European Association of Dermato-Oncology [EADO]) emphasize a dual therapeutic strategy based on whether a patient presents with isolated, solitary lesions or widespread field cancerisation (multiple keratoses scattered across a photodamaged field).

                                  Actinic Keratoses Management
                                              │
             ┌────────────────────────────────┴────────────────────────────────┐
             ▼                                                                 ▼
   Solitary / Discrete Lesions                                  Multiple Lesions / Field Cancerisation
   (Olsen Grade 1–3, no wide field)                             (≥ 3–5 lesions in confluent photodamaged field)
             │                                                                 │
             ▼                                                                 ▼
   Lesion-Directed Therapies                                         Field-Directed Therapies
   ├── Cryosurgery (Liquid N2, -196°C)                               ├── 5-Fluorouracil (4% or 5% cream)
   │   └── Open spray, 1–2 cycles, 5–15 sec                          ├── Imiquimod (5% or 3.75% cream)
   ├── Curettage & Electrodessication (C&E)                          ├── Diclofenac 3% in Hyaluronic Acid Gel
   └── Surgical Excision (for suspected cSCC)                        └── Photodynamic Therapy (PDT)
                                                                         ├── Conventional Red-Light PDT (630 nm)
                                                                         └── Daylight PDT (dPDT, painless, natural daylight)

Lesion-Directed Therapies

1. Cryosurgery (Liquid Nitrogen, -196°C):
   • Method: Open-spray technique held 1 to 1.5 cm perpendicular to the lesion surface, treating the lesion plus a 1–2 mm halo of perilesional tissue.
   • Dosing: One to two freeze-thaw cycles of 5 to 15 seconds freeze time (longer freeze times of 20–30 seconds for thicker Olsen Grade 2–3 lesions or Bowen disease).
   • Biophysical Mechanisms: Keratinocytes undergo lethal intracellular ice crystallization and cell membrane rupture at -20°C to -30°C. Crucially, melanocytes are exquisitely sensitive to cold injury and are destroyed at -5°C.
   • Clinical Trap: Post-inflammatory hypopigmentation is permanent and unavoidable when freezing temperatures dip below -5°C. Candidates must warn patients—particularly those with Fitzpatrick skin types III–VI—regarding permanent depigmented macules.
2. Curettage and Electrodessication (C&E):
   • Mechanical debridement with a sharp dermal curette down to firm, fibrous dermis, followed by superficial electrosurgical coagulation.
   • Advantage: Yields a tissue specimen for histological examination to confirm the absence of invasive cSCC.
3. Surgical Excision:
   • Reserved for very thick, indurated, or ulcerated Olsen Grade 3 lesions, cutaneous horns, erythroplasia of Queyrat, and lesions where invasive carcinoma cannot be excluded. A 3 to 4 mm margin is standard for suspected in situ disease.

Field-Directed Therapies

1. 5-Fluorouracil (5-FU) Topical Therapy:
   • Mechanism: A pyrimidine analog antimetabolite that undergoes intracellular phosphorylation into 5-fluoro-2'-deoxyuridine monophosphate (FdUMP). FdUMP forms a stable ternary covalent complex with thymidylate synthase and 5,10-methylenetetrahydrofolate, permanently inhibiting thymidylate synthesis. This depletes thymidine triphosphate (dTTP), blocking DNA synthesis and triggering cell death preferentially in rapidly dividing, dysplastic cells.
   • Formulations and Regimens:
     • 5-FU 5% cream: Applied twice daily for 2 to 4 weeks.
     • 5-FU 4% cream: Applied once daily for 4 weeks (improved compliance).
     • 5-FU 0.5% + Salicylic Acid 10% solution: Applied once daily for up to 12 weeks; the salicylic acid acts as a keratolytic agent enhancing 5-FU penetration into hyperkeratotic lesions.
   • Reaction Cascade: Patients proceed through four obligatory clinical stages: Erythema → Vesiculation/Blistering → Erosion/Necrosis → Re-epithelialisation. Clinicians must prepare patients: severe, unsightly inflammatory crusting and erosions are on-target biological responses, not an allergic contact dermatitis.
2. Imiquimod Topical Therapy:
   • Mechanism: Synthetic imidazoquinoline immune response modifier. It acts as an agonist at Toll-like receptor 7 (TLR-7) on plasmacytoid dendritic cells, monocytes, and macrophages. Receptor engagement triggers downstream MyD88 signaling and activates NF-κB, inducing robust synthesis and secretion of pro-inflammatory cytokines: interferon-alpha (IFN-α), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α). These cytokines stimulate a cytotoxic T-lymphocyte (CD8+) and natural killer (NK) cell-mediated immune response directed against mutated keratinocytes.
   • Dosing Regimens:
     • Imiquimod 5% cream: Applied 3 times weekly (e.g., Monday, Wednesday, Friday) at bedtime for 4 weeks. After a 4-week treatment-free interval, an additional 4-week cycle may be administered if residual lesions persist.
     • Imiquimod 3.75% cream: Applied once daily across a wider field (up to 200 cm² on face/scalp) in two 2-week treatment cycles separated by a 2-week rest period.
   • Adverse Effects: Local erythema, ulceration, crusting, and systemic flu-like symptoms (headache, fever, myalgias) mediated by circulating IFN-α.
3. Diclofenac 3% in 2.5% Hyaluronic Acid Gel:
   • Mechanism: Non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase-1 and -2 (COX-1/COX-2), thereby blocking the conversion of arachidonic acid into prostaglandin E2 (PGE2). Downregulation of PGE2 restores physiological caspase-dependent apoptosis, reduces pro-angiogenic vascular endothelial growth factor (VEGF), and curtails cellular proliferation. The 2.5% hyaluronic acid polymer vehicle forms a cutaneous depot, maintaining high local epidermal drug concentrations while minimizing systemic absorption.
   • Dosing Regimen: Applied twice daily for 60 to 90 days.
   • Clinical Profile: Exceptionally well-tolerated with only mild pruritus or dry scaling. Ideal for frail, elderly patients unable to endure the severe inflammatory necrosis caused by 5-FU or imiquimod, though complete clearance rates (~40–50%) are lower.
4. Photodynamic Therapy (PDT): Conventional vs Daylight PDT (dPDT):
   • Underlying Photochemical Principles: Application of a prodrug—either 5-aminolaevulinic acid (5-ALA) or its lipophilic methyl ester methyl aminolevulinate (MAL). Because dysplastic and neoplastic keratinocytes feature upregulated active membrane transporters, increased porphobilinogen deaminase, and deficient ferrochelatase, they preferentially convert ALA/MAL into Protoporphyrin IX (PpIX) via the intracellular heme biosynthetic pathway.
   • Conventional Red-Light PDT:
     • The photosensitizer (MAL or ALA) is applied under an occlusive dressing for 3 hours. Accumulation of intracellular PpIX reaches high peak concentrations.
     • The field is subsequently illuminated with narrow-band red light (wavelength ~630 nm, total dose ~37 J/cm²), which penetrates 2–3 mm into tissue.
     • Photoexcitation of PpIX transfers energy to ground-state molecular oxygen, generating reactive oxygen species (principally singlet oxygen [¹O₂]). Singlet oxygen causes rapid mitochondrial membrane collapse, cytochrome c release, and widespread apoptosis and necrosis of dysplastic cells.
     • Major Drawback: Severe, burning pain during illumination (VAS pain score 7–8/10), requiring cold air analgesia, nerve blocks, or treatment interruptions.
   • Daylight Photodynamic Therapy (dPDT):
     • Developed by European investigators to circumvent the debilitating pain of conventional PDT.
     • Protocol: Chemical sunscreen (SPF 50+ containing organic filters only, avoiding physical filters like titanium dioxide or zinc oxide that scatter visible light) is applied to sun-exposed areas. Fifteen minutes later, light surface curettage removes superficial crusts, and a thin layer of MAL or ALA cream is applied. Within 30 minutes of cream application, the patient goes outdoors into continuous natural daylight for exactly 2 hours.
     • Physiological Rationale for Painless Action: In daylight PDT, natural daylight (encompassing both blue Soret bands at ~405 nm and red absorption bands at 630 nm) immediately and continuously photoactivates and photobleaches PpIX as quickly as it is synthesized in the mitochondria. By preventing the accumulation of high peak levels of intracellular PpIX, intense, synchronous depolarization of cutaneous C-nociceptive nerve fibers is entirely prevented.
     • Clinical Efficacy: Large European randomized controlled trials demonstrate that daylight PDT achieves complete lesion clearance rates (70–85%) identical to conventional red-light PDT, while reducing visual analogue pain scores to near zero (VAS 1–2/10).

---

Comprehensive Comparison of AK Therapeutic Modalities